AN2 Therapeutics, Inc.

Current report (Form 8-K) · Jun 9, 2026 · Item 5.07

Company

Documents

Primary topic

Item 5.07

Filed

Jun 9, 2026

Filing summary Workforce analysis SEC documents(4)Filing text

Type

8-K

File

antx-20260603.htm

Document text
8-K · antx-20260603.htm iXBRL 0001880438 2026-06-03 2026-06-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 03, 2026 AN2 Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41331 82-0606654 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1300 El Camino Real, Suite 100 Menlo Park , California 94025 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: 650 331-9090 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock ANTX The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07 Submission of Matters to a Vote of Security Holders. On June 3, 2026, AN2 Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). Present at the beginning of the Annual Meeting in person or via proxy were the holders of 22,741,535 shares of common stock of the Company, representing 63.18% of the 35,995,545 shares of common stock outstanding as of the close of business on April 15, 2026, the record date for the Annual Meeting, and constituting a quorum for the transaction of business. At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 22, 2026. The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for or against each matter and, if applicable, the number of votes withheld, abstentions and broker non-votes with respect to each matter. 1. To elect the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors until the Company’s 2029 annual meeting of stockholders or until their respective successors have been elected or appointed. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Kabeer Aziz 13,547,536 3,958,874 5,235,125 Gilbert Lynn Marks, M.D. 15,947,854 1,558,556 5,235,125 Rob Readnour, Ph.D. 15,920,563 1,585,847 5,235,125 2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions 22,724,674 13 16,848 3. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AN2 Therapeutics, Inc. Date: June 8, 2026 By: /s/ Joshua Eizen Joshua Eizen Chief Legal Officer and Chief Operating Officer

Document text

8-K · antx-20260603.htm iXBRL

0001880438 2026-06-03 2026-06-03

  
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
  
 FORM 8-K
  
 CURRENT REPORT
 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 Date of Report (Date of earliest event reported): June 03, 2026

  
  
 AN2 Therapeutics, Inc.
 (Exact name of Registrant as Specified in Its Charter)
  
  

 Delaware

 001-41331

 82-0606654

 (State or Other Jurisdiction
of Incorporation)

 (Commission File Number)

 (IRS Employer
Identification No.)

  

  

  

  

  

 1300 El Camino Real, Suite 100

  

 Menlo Park , California

  

 94025

 (Address of Principal Executive Offices)

  

 (Zip Code)

  

 Registrant’s Telephone Number, Including Area Code: 650 331-9090

  

  

 (Former Name or Former Address, if Changed Since Last Report)
  
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

 Trading
Symbol(s)

  

Name of each exchange on which registered

 Common Stock

  

 ANTX

  

 The Nasdaq Global Select Market

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 Emerging growth company ☒
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
  

 Item 5.07 Submission of Matters to a Vote of Security Holders.
 On June 3, 2026, AN2 Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). Present at the beginning of the Annual Meeting in person or via proxy were the holders of 22,741,535 shares of common stock of the Company, representing 63.18% of the 35,995,545 shares of common stock outstanding as of the close of business on April 15, 2026, the record date for the Annual Meeting, and constituting a quorum for the transaction of business.
 At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 22, 2026. The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for or against each matter and, if applicable, the number of votes withheld, abstentions and broker non-votes with respect to each matter.
 1. To elect the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors until the Company’s 2029 annual meeting of stockholders or until their respective successors have been elected or appointed. The voting results were as follows:
  

 Name

  

 Votes For

  

 Votes Withheld

  

 Broker
Non-Votes

 Kabeer Aziz

  

  13,547,536

  

 3,958,874

  

  5,235,125

 Gilbert Lynn Marks, M.D.

  

 15,947,854

  

  1,558,556

  

 5,235,125

 Rob Readnour, Ph.D.

  

 15,920,563

  

 1,585,847

  

 5,235,125

  
 2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows:

 Votes For

  

 Votes Against

  

 Abstentions

 22,724,674

  

  13

  

 16,848

 3.

 SIGNATURES
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  

  

 AN2 Therapeutics, Inc.

  

  

  

  

 Date:

 June 8, 2026

 By:

 /s/ Joshua Eizen

  

  

  

 Joshua Eizen
Chief Legal Officer and Chief Operating Officer

Open on SEC

All SEC filings Signals